Howe & Rusling’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-69
Closed -$4K 325
2022
Q3
$4K Sell
69
-13
-16% -$840 ﹤0.01% 689
2022
Q2
$4K Buy
82
+10
+14% +$579 ﹤0.01% 668
2022
Q1
$5K Sell
72
-23
-24% -$1.57K ﹤0.01% 635
2021
Q4
$7K Sell
95
-25
-21% -$1.48K ﹤0.01% 583
2021
Q3
$6K Sell
120
-17
-12% -$740 ﹤0.01% 575
2021
Q2
$6K Hold
137
﹤0.01% 558
2021
Q1
$6K Buy
+137
New +$5.11K ﹤0.01% 559

Other funds holding ACLS

Howe & Rusling's ACLS Position: Q4 2022 in Review

Howe & Rusling sold out of Axcelis (ACLS) in Q4 2022, closing a stake of 69 shares — an estimated $4K sold.

Howe & Rusling first reported a position in ACLS in Q1 2021 and held it in 7 quarters. The position peaked at $7K in Q4 2021. 325 funds tracked by Wall St. Rank hold ACLS as of Q4 2022.

  • Howe & Rusling reported no remaining Axcelis position as of Q4 2022 after selling out during the quarter.
  • Howe & Rusling sold 69 Axcelis shares in Q4 2022, an estimated $4K.
  • Howe & Rusling first reported a position in Axcelis in Q1 2021 and held it in 7 quarters.
  • Howe & Rusling's Axcelis position peaked at $7K in Q4 2021.
  • 325 funds tracked by Wall St. Rank held Axcelis as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.